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ABSTRACT
Background: Certain immunotoxic peptides from gluten are resistant
to gastrointestinal digestion and can interact with celiac-patient factors
to trigger an immunologic response. A gluten-free diet (GFD) is the
only effective treatment for celiac disease (CD), and its compliance
should be monitored to avoid cumulative damage. However, practical
methods to monitor diet compliance and to detect the origin of an
outbreak of celiac clinical symptoms are not available.
Objective: We assessed the capacity to determine the gluten in-
gestion and monitor GFD compliance in celiac patients by the de-
tection of gluten and gliadin 33-mer equivalent peptidic epitopes
(33EPs) in human feces.
Design: Fecal samples were obtained from healthy subjects, celiac
patients, and subjects with other intestinal pathologies with different
diet conditions. Gluten and 33EPs were analyzed by using immuno-
chromatography and competitive ELISA with a highly sensitive
antigliadin 33-mer monoclonal antibody.
Results: The resistance of a significant part of 33EPs to gastroin-
testinal digestion was shown in vitro and in vivo. We were able to
detect gluten peptides in feces of healthy individuals after consump-
tion of a normal gluten-containing diet, after consumption of a GFD
combined with controlled ingestion of a fixed amount of gluten, and
after ingestion of,100 mg gluten/d. These methods also allowed us
to detect GFD infringement in CD patients.
Conclusions: Gluten-derived peptides could be sensitively detected in
human feces in positive correlation with the amount of gluten intake.
These techniques may serve to show GFD compliance or infringement
and be used in clinical research in strategies to eliminate gluten im-
munotoxic peptides during digestion. This trial was registered at
clinicaltrials.gov as NCT01478867. Am J Clin Nutr 2012;95:
670–7.
INTRODUCTION
Gluten is the storage protein of wheat, rye, barley, and oats and
is not well tolerated in genetically predisposed individuals who
suffer from CD4. Although most dietary proteins are digested
into simple amino acids, dipeptides, and tripeptides by gastro-
intestinal proteases, gluten proteins are not completely digested
and remain in the gastrointestinal tract (1, 2). The a-gliadin 33-
mer is one of the digestion-resistant gluten peptides that is
highly reactive to isolated celiac T cells and is the main im-
munodominant toxic peptide in celiac patients (3–5).
A lifelong GFD is currently the only available treatment for
CD patients. Clinical manifestations associated with untreated
CD, such as osteoporosis, anemia, depression, and infertility, can
ameliorate with a GFD. Therefore, strict adherence to a GFD is
essential to reduce symptoms, avoid nutritional deficiencies, and
improve quality of life. However, according to several reports,
dietary transgression is relatively frequent (32.6–55.4%) in celiac
patients (6). In addition, a part of the celiac population (5–10%)
does not respond to a GFD and has persistent villous atrophy with
continued malabsorption. Although it is possible for patients to
relapse despite a strict GFD, involuntary infringement or hy-
persensitivity to small amounts of gluten can also trigger the
symptoms of the disease. Thus, an accurate marker that allows
short-term monitoring of GFD compliance is needed. Approxi-
mately 1–2% of patients, mainly adults, can develop RCD, which
is characterized by symptomatic malabsorption and persistent
villous atrophy despite a strict GFD (7, 8). A demonstration of
a lack of gluten in the diet of RCD patients would help in the
differential diagnosis (9). Direct measures of dietary trans-
gressions, such as mucosal inflammation and antitissue trans-
glutaminase or antigliadin antibody concentrations in serum
could be used to confirm GFD compliance. However, because
a decrease in antibody titers may take years to achieve even when
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an individual is supposedly compliant with a GFD, the effec-
tiveness of these markers to monitor gluten ingestion is unclear
(10–12). Furthermore, there is no effective method to rule out the
possibility that the symptoms of RCD are not due to a hyper-
sensitive intolerance to gluten traces or are associated with in-
voluntary gluten exposure (13).
The G12 and A1 moAbs against the main immunogenic
epitope of the a-gliadin 33-mer have proved to be very useful for
the detection of toxic peptides in food samples and for the en-
zymatic detoxification of gluten in clinical research (14, 15). In
this study, we evaluated the feasibility of monitoring gluten
ingestion by detection of 33EPs in feces. Detection of whole and
digested gluten in feces would be useful in clinical research
studies and GFD monitoring, as well as for the precise diagnosis
of RCD. Our results suggested that immunologic methods that
use the G12 moAb could be a specific and reliable novel tool for
the detection of prolamine immunotoxic peptides in feces and,
thus, useful in research and clinical monitoring of CD.
SUBJECTS AND METHODS
Subjects
Subjects were recruited at 2 different referral centers after ap-
proval by the local ethics committee. Twenty-six healthy subjects
(16 female and 10 male subjects; age range: 3–42 y) were enrolled
in the study. Exclusion criteria included the presence of known
medical disease, digestive disease symptoms, family history of CD,
use of prescription medications, and use of antibiotics or probiotics
in the previous 2 mo to the inclusion in the study. All subjects had
normal hemoglobin levels, serum biochemical analysis, and renal
and hepatic function.
A total of 53 celiac patients (35 female and 18 male subjects;
age range: 1–12 y), 7 subjects of whom had active disease and 46
subjects of whom consumed a GFD for .2 y, were included in
the study. The diagnosis of CD was based on the detection of
IgA antiendomysial and IgA antitissue transglutaminase anti-
bodies in serum and confirmed by a small intestinal biopsy.
Biopsy specimens were obtained by using gastrointestinal en-
doscopy and evaluated according to the Marsh criteria for di-
agnosis of CD (16). All patients included in the study showed
Marsh 3 grade villous atrophy at the time of the diagnosis.
Six control subjects (5 women and 1 man; age range: 33–65 y)
with functional dyspepsia according to the Rome III criteria were
also included in the study. All subjects showed normal duodenal
mucosa (Marsh 0) and negative serology for CD.
TheLocal Ethics Committee of theHospitalUniversitario deLeo´n
(Leon, Spain) and the “Hospital de Valme” (Seville, Spain) approved
the study, and informed consent was obtained from subjects.
Fecal sampling
Fresh stools from healthy subjects were obtained during dif-
ferent diet conditions as follows: 1) before initiation of the GFD
while on a normal gluten-containing diet, 2) on each day of the
GFD, 3) on the fourth day after administration of 9 g gluten/d, 4)
on the fourth day after administration of 30 g gluten/d, and 5) on
each day of administration of a gluten microdose (50 mg to 1 g/d).
In celiac patients, fecal samples were collected at different
stages of the disease as follows: before the start of a GFD in active
patients, while following a GFD in patients in remission, and
during a gluten challenge in patients in remission. In nonceliac
controls with other intestinal pathologies, fecal samples were
collected while subjects followed a normal gluten-containing
diet. All samples were homogenized and aliquoted within 3 h of
defecation and stored at 280C.
Experimental design
Analysis of the presence of gluten and 33EPs in feces of
subjects was carried out blinded, and dietary compliance was
assessed retrospectively by a patient or parent interview.
Extraction of peptides/prolamines from feces
Prolamines from feces were extracted by mixing 1 g feces with
10 mL of 60% (vol:vol) ethanol in a rotary shaker for 1 h at room
temperature. Then, the suspension was centrifuged at 2500 · g
for 10 min, and the supernatant fluid was obtained.
G12 moAb and 33-mer peptide
The G12 moAb, its derived horseradish peroxidase–conjugated
moAb, and the 33-mer peptide used in the study were from
Biomedal SL.
Simulated gastrointestinal digestion
To reproduce gastric digestion in vitro, PWG gliadin was
incubated at 37C for 60 min in HCl solution (pH 2.0) that
contained 0.60 mg pepsin/mL (Sigma). Gastric digests were
adjusted to pH 6.0 with sodium phosphate buffer and subjected
to a simulated duodenal digestion by sequential addition of the
pancreatic enzymes trypsin (0.375 mg/mL) and chymotrypsin
(0.375 mg/mL) at 37C for 30 min (both from Sigma) (17).
G12 moAb immunochromatographic test for detection of
gluten
The immunochromatographic assay was modified from the
guidelines of the manufacturer (GlutenTox Stick; Biomedal SL).
After prolamine extraction with ethanol 60%, samples were
serially diluted (1:10–1:20,000) in the buffer solution provided by
the manufacturer for concentrations that corresponded to 6, 25,
50, 100, 250, and 500 ppm. The immunochromatographic strips
were dipped into the sample solutions (300 lL each) for 10 min
and allowed to air dry afterward.
SDS-PAGE fractionation and Western blotting
SDS-PAGE was prepared with 15–18% acrylamide, and tri-
cine–SDS-PAGE was performed as described by Sousa et al (18).
Proteins and peptides in the gel were silver stained or transferred
to a polyvinylidene fluoride membrane. Membranes were in-
cubated with G12 moAb after washing and incubating with
antimouse IgG-phosphatase antibody (Sigma) (17).
Competitive ELISA
Relative amounts of samples that contained immunotoxic
epitopes were quantified by a G12 competitive ELISA (15, 17).
Maxisorp microtitre plates (Nunc) were coated with PWG gliadin
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solution and incubated overnight at 4C. The plates were washed
with PBS-Tween 20 buffer and blocked with blocking solution
(PBS and 5% nonfat milk) for 1 h at room temperature. Serial
dilutions were made of the 33-mer peptide and the samples in
PBS-bovine serum albumin 3%, to each of which was added
horseradish peroxidase–conjugated G12 moAb solution. The
samples were preincubated at room temperature and added to
the wells. After 30 min of incubation at room temperature, the
plates were washed, and substrate solution (TMB; Sigma) was
added. The reaction was stopped with 1 M sulfuric acid, and the
absorbance at 450 nm was measured (microplate reader
UVM340; Asys Hitech GmbH).
Statistical analysis
All experiments were carried out in triplicate, and all statistical
analyses were performed with SPSS 18.0 forWindows (SPSS Inc).
PWG gliadin and 33-mer assays were expressed as means6 SDs.
Differences between groups were examined by 1-factor ANOVA,
and individual means were compared by using a Bonferroni-
corrected Student’s t test. The fecal 33-mer peptide assays were
expressed as medians and ranges and 25th and 75th percentiles.
Differences between groups were examined by using the Fried-
man’s and Wilcoxon’s tests. A statistical probability of P , 0.05
was considered significant for all analyses.
RESULTS
Quantification of PWG gliadin toxic peptides by the G12
moAb after simulated gastrointestinal digestion
The gliadin 33-mer peptide contains 3 copies of the QPQLPY
epitope. The G12 moAb specifically recognizes the QPQLPY
epitope as well as other immunoreactive peptides in toxic pro-
lamines (15). To evaluate the ability of the G12 moAb to detect
the reactive peptides formed after gastrointestinal digestion of
gliadin, we first subjected PWG gliadin to simulated gastric
digestion by using pepsin (the major protease present in the
stomach) followed by simulated intestinal digestion by using the
pancreatic enzymes trypsin and chymotrypsin. The prolamine
protein profile obtained after simulated digestion and the extent
of the digestion were confirmed by SDS-PAGE. Electrophoretic
separation of intact gliadin revealed intense bands of a, b, and c
gliadins (molecular weight: 33–45 kDa) and weak bands of
omega gliadin (molecular weight: 50–67 kDa). Digestion of
gliadin with pepsin gave rise to smaller peptidic fragments ,25
kDa each, and additional digestion with trypsin and chymo-
trypsin generated even smaller peptides as a result of the enzy-
matic hydrolysis (Figure 1A). Additional Western blot analysis
confirmed the recognition of the different reactive peptides by the
anti–33-mer G12 moAb, even after treatment with gastric and
pancreatic enzymes (Figure 1B).
To test the capacity of the G12 moAb to quantify the gliadin
toxic peptides obtained after gastrointestinal digestion, a G12
competitive ELISA to measure the concentration of G12-moAb–
related epitopes was performed on simulated gastrointestinal
digests of PWG gliadin. This technique was chosen over sand-
wich ELISA because of its capacity to detect both intact and
small protein fragments. The latter detection could be under-
estimated by sandwich ELISAs because they require2 different
epitopes per molecule. Gastric digestion of gliadin led to a slight
increase in the concentration of reactive 33-mer peptides with
respect to that of intact PWG gliadin (intact PWG gliadin: 21.6 ng
33-mer/lg; gastric-digested PWG gliadin: 24.5 ng 33-mer/lg).
This increase could have been due to hidden epitopes of glia-
din that became more accessible and allowed the interaction with
the anti–33-mer moAb after digestion with gastric enzymes. Al-
though with lower intensity (7.5 ng 33-mer/lg), the G12 moAb
continued to recognize the gliadin peptides formed after intestinal
digestion, which possibly indicated that two-thirds of the G12-
recognized epitopes were destroyed by intestinal enzymes (Fig-
ure 1C).
FIGURE 1. The mean (6SD) relative affinity of G12 moAb to
immunotoxic peptides derived from PWG gliadin after simulated
gastrointestinal digestion. A and B: SDS-PAGE and Western blot of PWG
gliadin, PWG gliadin + pepsin, and PWG gliadin + pepsin + trypsin/
chymotrypsin. Samples were stained with silver (A) or after transfer to
a polyvinylidene fluoride membrane and incubated with G12 moAbs (B).
C: Competition assay that measured the affinity of the horseradish peroxidase–
conjugated G12 moAb to gliadin peptides present in gastrointestinal digests.
Three assays were performed with samples run in triplicate. moAb,
monoclonal antibody; MW, molecular weight marker; PWG, Prolamin
Working Group.
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To verify that the 33-mer peptide remained intact after gastric
and intestinal proteolysis, the 33-mer peptide was subjected to
simulated gastrointestinal digestion, and its concentration was
determined after each digestive step by using a G12 competitive
ELISA. The 33-mer peptide concentration after gastric digestion
(194 lg/mL) or intestinal digestion (169 lg/mL) did not vary
significantly from that of nondigested 33-mer peptide (186 lg/mL)
(Figure 2, A and B). These results were confirmed by Western
blot analysis in which a single band of ~3.5 kDa in size was seen
in the undigested and the sequentially digested 33-mer samples
(33-mer theoretical molecular weight: 3.9 kDa) (Figure 2C).
The ability of the G12 moAb to detect hydrolyzed gliadin was
also evaluated by using G12-moAb–based immunochromato-
graphic strips. The detection limit for gliadin and hydrolyzed
gliadin was 30 ng/mL (6 ppm of gluten) and 50 ng/mL (10 ppm of
hydrolyzed gluten), respectively; whereas for the 33-mer peptide
and the 33-mer peptide subjected to digestion, the detection limit
was 0.5 ng/mL.
These sets of experiments show that a substantial portion of
G12-moAb detectable prolamine epitopes from ingested food
were resistant to gastrointestinal digestion and, thus, could be
detected at any level of the gastrointestinal tract (at least in the
absence of gut microflora).
In vivo monitoring of gluten peptides and proteins in feces
of healthy individuals after consumption of a controlled
gluten-containing diet
To test the feasibility and sensitivity to detect gluten in feces of
individuals after consumption of a normal gluten-containing diet,
we collected fecal samples from healthy subjects (n = 15) who
received a nonstandardized diet in which gluten was consumed
daily (at least one piece of white bread at breakfast and normal
ingestion of, eg, pasta and cookies), and we analyzed the pres-
ence of gluten polypeptides by using G12 immunochromato-
graphic strips and G12 competitive ELISA. The concentration of
gluten peptides in feces by using G12 immunochromatographic
strips increased 100-fold above the detection limit in all in-
dividuals after consumption of a normal gluten-containing diet.
The G12 competitive ELISA confirmed the presence of 33EPs in
the fecal samples of all subjects after consumption of a normal
gluten-containing diet and showed a gluten peptide excretion
that ranged between 226 and 87,092 ng 33EPs/g feces, which
suggested that the degree of gluten hydrolysis was strongly af-
fected by the diet, type of gluten-containing food, and/or in-
dividual characteristics such as the gut microflora.
After proving the ability to detect gluten in feces by immu-
nologic methods, we sought to determine the time needed for the
reactive gluten peptide to be excreted. For this assessment, a group
of healthy volunteers, who consumed a normal gluten-containing
diet, received a GFD for 1 wk, and fecal samples were collected
every day for the 1-wk-long gluten-free period. The time necessary
for the gluten reactive peptide to become undetectable ranged from
2 to 4 d as determined by G12 immunochromatographic strips and
G12 competitive ELISA (Figure 3).
Given the variability shown in the concentration and time to
excretion of gluten-reactive peptides across subjects after con-
sumption of a normal gluten-containing diet, the next experi-
ments to monitor the presence of 33EPs in feces were performed
with a fixed amount of gluten. Thus, to examine whether the
amount of gluten consumption correlated with the amount of
gluten excretion, 11 healthy volunteers were subjected to a strict
GFD for 1 wk, after which a fixed amount of 9 g of gluten, which
was distributed across the main meals, was administered every
day for 4 consecutive days followed by 30 g of gluten for 4
additional days. One single type of gluten (without previous heat
treatment) was used in all cases to avoid variability because of the
administration of gluten from different sources. For quantifica-
tion by using G12 immunochromatographic strips, the stool
samples were serially diluted after collection to cover a range
between 6 and 500 ppm. After consumption of a normal gluten-
containing diet, all subjects showed gluten excretion in feces,
with values that exceeded 500 ppm (Figure 4), whereas all fecal
samples collected during the period in which subjects consumed
FIGURE 2.Mean (6SD) resistance of 33-mer peptides to cleavage by gastrointestinal enzymes. A: Amino acid sequences of the 33-mer peptide. The G12
moAb recognition sequence in the 33-mer peptide is in bold-face type. B: Competition assay for the detection of 33-mer peptide by G12 moAb after treatment
with pepsin, trypsin, and chymotrypsin. Three assays were performed with samples run in triplicate. C: Western blot analysis of 33-mer peptide by the G12
moAb after treatment with gastrointestinal enzymes. moAb, monoclonal antibody; MW, molecular weight marker.
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a GFD had gluten amounts below the detection limit of the
method. When subjects consumed 9 g gluten/d, the amount of
gluten detected in feces was .250 ppm in all but one case, which
contained between 6 and 25 ppm, and when subjects consumed
30 g gluten/d, excreted amounts were.500 ppm (Figure 4, A and
B), which represented a 100-fold increase over the detection limit.
This result showed an approximate correlation between the
amount of gluten consumed and the amount of gluten peptides
with G12 epitopes excreted in feces. In addition, Western blot
analysis showed G12 moAb reactivity for all samples (positive
controls, GFD + 9 g gluten, and GFD + 30 g gluten), except for
those obtained during the GFD period (Figure 4, C and D). G12
competitive ELISA, which was used to determine the concen-
tration of toxic peptides in these samples, showed the presence of
33EPs in all stool samples collected during the normal gluten
containing–diet period, whereas the amounts of toxic peptides
were below the quantification limit of the method (5.4 pg 33EPs/
mg sample) when the subjects were maintained on a GFD. The
range of 33EPs in subjects who consumed 30 g gluten/d was 6.7–
28.0 ng 33EPs/mg feces (1240–5185-fold above the detection
limit), which was significantly higher (P = 0.018) than in subjects
who consumed 9 g gluten/d, in whom the range was 3.5–9.6 ng
33EPs/mg feces (648–1778-fold above detection limit) (Figure
5). These results were in agreement with those obtained with
immunochromatographic strips.
In a significant proportion of celiac patients, an abnormal small
bowel morphology persists despite a GFD, probably because of
the persistent ingestion of trace amounts of gluten. Catassi et al
(19) showed that treatment of CD required the ingestion of ,50
mg gluten/d. To test whether the G12-moAb–based methods
were capable of detecting these small amounts of gluten in fecal
samples, increasing doses of gluten (from 50 mg to a maximum
of 1g gluten/d) were administered after an initial 50-mg mi-
crodose. Subjects were given a standard piece of white bread
that contained 25 mg gluten per piece of bread, and the glu-
ten content in the stools was measured by using G12 immuno-
chromatographic strips and G12 competitive ELISA. Gluten
amounts in feces became detectable beyond the 50-mg dose
of gluten, and the individual variations seen were probably due
to individual differences and variations in daily food consump-
tion.
Quantification of gluten peptides and proteins in feces of
CD patients after consumption of a gluten-containing diet
and GFD
To determine whether the G12-moAb–based methods were
suitable for monitoring gluten ingestion in celiac patients, a study
was conducted in CD patients to measure gluten peptides and
proteins in feces. The study included 43 patients with CD in re-
mission who had been consuming a long-term GFD (.2 y), 7
patients with active disease who were consuming normal gluten-
containing diet up to the moment of diagnosis, and 3 CD patients
who were consuming a GFD and were subjected to a gluten
challenge. Non-CD subjects with other intestinal pathologies and
healthy volunteers were used as control subjects. In 42 of 43
patients with CD in remission the amounts of toxic gluten pep-
tides in feces were below the detection limit of the method. The
remaining patient had gluten peptide amounts .6 ppm. When
interviewed at the end of the study, this supposedly noncompliant
patient confirmed consumption of cake (which contained gluten)
during the study. In patients with active CD, the gluten shown in
feces collected during the normal gluten-containing diet period
was .6 ppm (range: 118–135 ng 33EPs/g feces).
FIGURE 3. Determination of the time to elimination of ingested gluten in healthy individuals subjected to a gluten-free diet for 7 d. A: Competitive assay
to determine the concentration of 33EPs (ng/g) in feces (n = 4). Each sample was analyzed in triplicate, and maximum, minimum, and 25th and 75th
percentiles are shown. B: One representative immunochromatographic-strip example of the trial performed with the samples collected during the study period
of one subject. Blue stripes represent an internal positive control that indicates that the stick worked properly; pink stripes indicate the presence of gluten. QL,
quantification limit; 33EPs, 33-mer equivalent peptidic epitopes.
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To assess the presence of gluten in feces of CD patients in
remission, patients in remission after consumption of a GFDwere
given a gluten-containing diet for 6 d, and their stools were
collected each day of the challenge period. The gluten challenge
was carried out to confirm the diagnosis of CD and at the request
of parents who were uncertain about the diagnosis. Out of the 3
patients who received the gluten challenge, 2 patients developed
symptoms of vomiting, abdominal pain, and diarrhea within the
first days of the administration of gluten and were excluded from
the study. However, in the patient who tolerated the gluten
challenge, fecal samples were collected for each of the 6 d that the
challenge lasted, and the amount of gluten excreted was analyzed
by using G12 antibody-based immunological methods to de-
termine whether there was gluten excretion and the amounts of
toxic peptides excreted during the period of gluten challenge.
According to G12 competitive-ELISA results (Figure 6), ex-
cretion of gluten peptides started on the third day of the gluten
challenge. Between days 3 and 6 of the challenge, fecal amounts
of gluten reactive peptides ranged between 417 and 7037 ng
33EPs/g feces. These results were corroborated by using G12
immunochromatographic strips. In non-CD control subjects with
other intestinal pathologies, the gluten content, although the sub-
jects consumed a normal gluten-containing diet, ranged between
201 and 29,076 ng 33EPs/g feces. The intraindividual and inter-
individual differences seen in excretion could have been related to
the diet, the type of gluten-containing food, and the variability in
fermentative degradation.
These results confirmed that the G12 immunologic methods
used for the detection of 33-mer gluten peptides were reliable
tools for the detection of GFD transgressions in patients with
active CD and with CD in remission after consumption of a GFD.
These methods could, therefore, be used to verify GFD com-
pliance to improve the diagnosis of cases refractory to the diet or
with acute symptoms and for prolamine detoxification therapies
in clinical research.
DISCUSSION
In this article, we describe a novel method to detect and
monitor the presence of immunodominant gluten peptides in
human feces on the basis of the use of the antigliadin 33-mer G12
antibody. To our knowledge, this was the first study to detect
gluten-derived peptides in feces of patients with CD or other
intestinal pathologies. The resistance of gluten peptides to
FIGURE 4. Detection of gluten in feces of healthy individuals subjected to a controlled gluten-containing diet. A: Semiquantitative analysis of gluten
peptides and proteins in feces of healthy individuals by using G12 immunochromatographic strips HL901–HL911 (studied subjects: n = 11). An asterisk
indicates that gluten traces were detected. B: One representative immunochromatographic-strip example of the trial performed with the samples collected
during the study period for one subject. Blue stripes represent an internal positive control that indicates that the stick worked properly; pink stripes indicate the
presence of gluten. C and D: SDS-PAGE and Western blot of gluten peptides and proteins extracted from feces. GFD, gluten-free diet; MW, molecular weight
marker; PWG, Prolamin Working Group.
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gastrointestinal digestion, in particular that of the immunotoxic
33-mer peptide, ensures that a significant part of the ingested
gluten peptides are excreted in feces, and thus recovery of
measurable amounts of the immunotoxic fraction in feces would
indicate that gluten has passed through the digestive tract and,
therefore, that gluten has been consumed. In this study, the anti–
33-mer G12-based immunoassays showed that .30% of the
gliadin-reactive peptides remained intact after hydrolysis during
in vitro simulated gastrointestinal digestion. However, the ab-
sorption of intact gliadin-reactive peptides along the gastroin-
testinal tract may vary between individuals. Diversity in the gut
microflora (microbiome) and in the accompanying diet could
have a dramatic impact on the resultant peptide concentration in
feces (20). Although a low digestion rate of gluten peptides
would reduce their absorption, most of the undigested gluten
peptides would be excreted, and either rapid immunochroma-
tographic strips or ELISAs could be used to detect gluten in-
gestion in feces.
A main application of these assays to measure gluten in feces
could be the monitoring of GFD compliance in CD patients. In
the current study, we observed that, despite a large variation
between individuals, there was a rough correlation between the
amount of gluten consumed and the amount of gluten excreted.
Differences in the amount of ingested gluten could be estimated
by using different methods, such as immunochromatographic
strips, competitive ELISA, and Western blot. Immunochroma-
tographic strips might be attractive as clinical standard assays in
a broad range of laboratories as well as in point-of-care settings.
However, the use of a G12 competitive ELISA could be more
suitable in situations that require a more quantitative analysis of
the sample such as when monitoring a GFD, identifying the
source of dietary infringement in CD patients, or assessing the
efficacy of novel therapies in the destruction of gluten toxic
peptides (4, 21).
Some authors (19) have suggested that prolonged ingestion of
50 mg gluten/d causes significant damage to the architecture of
the small intestine in patients who have begun treatment of CD.
Furthermore, high consumption of gluten (1–5 g/d), although
lower than that of the nonceliac population, causes a relapse of
the disease at clinical, serologic, and histologic amounts. As
a result, it is important to know the capacity of the analytic
method used to detect ingestion of small amounts of gluten. Our
results indicated that the ingestion of gluten amounts as low as 50
mg in processed bread could be detected in feces.
Currently, there are no validated methods to monitor ad-
herence to a GFD. Antitissue transglutaminase antibodies have
been proposed as markers of GFD compliance; however their
effectiveness is still not clear (10). IgA-class antibodies can
take several months to decrease, and IgG-class antibodies can
take 1 y to decrease, after the antigen source has been
eliminated from the diet. Therefore, serology does not predict
recovery (8) and is not useful for follow-up. The use of serial
endoscopies is not useful either because it is not considered
an ethical practice. Other tests suggested as suitable diet-
monitoring markers were the permeability test and fecal
calprotectine (12, 13). We can measure the consequences of
dietary transgressions, such as mucosal inflammation, but
there is no way to show gluten intake and avoid the harmful
aftermaths. Dietary interviews, although shown to be helpful
in the determination of diet compliance, are often not possible
to standardize, are subjective or rely on a truthful response
from the patient, and cannot identify involuntary infringe-
ments. Our results showed that a broad range of gluten
amounts (from 50 mg to 30 g) could be detected in feces of
pediatric patients who were recently diagnosed with CD, were
in remission, or were subjected to a gluten challenge; how-
ever, future studies that involved adult CD patients should be
performed. These studies confirmed the use of G12 im-
munoassays to more accurately diagnose and monitor the
FIGURE 5. Competitive ELISAs that used horseradish peroxidase–
conjugated G12 monoclonal antibodies to test the relation between the
gluten proteins ingested and excreted and the 33-mer–related peptide
content in feces. The concentration of 33EPs (ng/mg) in feces after
a controlled gluten-containing diet is shown. The concentration of 33-mer
peptide was determined by comparison with a synthetic 33-mer standard
curve (n = 11). Median, maximum, minimum, and 25th and 75th
percentiles are shown. Three assays were performed with samples run in
triplicate. GFD, gluten-free diet; 33EPs, 33-mer equivalent peptidic epitopes.
FIGURE 6. Analysis of mean (6SD) gluten amounts excreted in the
feces of a celiac patient subjected to a gluten challenge for 6 d. Amounts
of toxic peptide (ng/g feces) were determined by using a G12 competitive
ELISA. Data were obtained from 3 independent experiments with samples
run in triplicate. GFD, gluten-free diet; 33EPs, 33-mer equivalent peptidic
epitopes.
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disease and, thus, their value to study nonresponsive patients
and to monitor adherence to a GFD.
In this study, we estimated the time of gluten toxic-peptide
excretion to be between 2 and 4 d. These results should be taken
into account if these methods are used in the diagnosis of gluten
intoxication or if acute CD symptoms appear in an individual
already treated with GFD.
Patients with RCD do not experience remission of symptoms
while consuming a strict GFD. The diagnosis of RCD requires the
exclusion of other diseases that can cause diarrhea and villous
atrophy and the confirmation of adherence to a strict GFD (7, 8).
A previous study showed that 82–90% of RCD patients referred
to 2 large tertiary care centers were consuming gluten and had
been improperly diagnosed of RCD (22). Moreover, there is no
effective method to rule out if RCD symptoms are due to hy-
persensitive to trace amounts of gluten or to involuntary gluten
exposure. The results obtained in the current study with patients
with active CD patients, in remission, or after a gluten challenge
demonstrated that these methods could be used to determine
uncontrolled gluten ingestion and might be a useful for studying
RCD (7, 8).
In a previous study, we showed that the reactivity of antigliadin
33-mer moAbs correlated with the potential immunotoxicity of
gluten proteins. T cell–reactivity analysis and enzymatic de-
toxification of gluten by glutenases showed that the signal of the
antigliadin 33-mer moAbs correlated with the sample’s potential
toxicity for celiac patients (4, 15, 21), which suggested that
glutenases were able to cleave the epitopes detected by these
antibodies. Therefore, the determination of the content of 33EPs
in feces could be used to monitor gluten detoxification of celiac
patients treated with novel enzymatic therapies (3, 21, 23),
proving the utility of these methods in experimental therapies for
CD.
In this article, we have shown how to monitor the consumption
of gluten by simple immunologic assays in feces and thereby
overcome some unresolved scientific and clinical problems in
celiac-patient monitoring, including 1) the monitoring of short
-term GFD compliance, 2) assessment of the efficacy of enzy-
matic therapies, and 3) how to diagnose gluten intoxication that
is due to involuntary food contamination. Researchers may want
to consider the use of these methods when designing clinical
trials in CD and to correctly interpret acute or refractory
symptoms in celiac patients. In conclusion, the resistance of
33EPs to gastrointestinal digestion and the use of G12 anti–33-
mer-based tests may be useful for monitoring dietary compli-
ance in CD patients due to its noninvasiveness, sensitivity, and
significant correlation with consumed gluten.
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